Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 13 Dec 2023 18:51 CET |
NAVAMEDIC | Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe | 20103015 Pharmaceuticals | Inside information |
| 01 Nov 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Nok et rekordkvartal med over 50 prosent vekst | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 01 Nov 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Record high quarter with above 50 percent growth | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 27 Oct 2023 11:13 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 3rd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Aug 2023 13:02 CEST |
NAVAMEDIC | Navamedic ASA - Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 18 Aug 2023 12:31 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 18 Aug 2023 11:56 CEST |
NAVAMEDIC | NAVAMEDIC ASA: Resolution to increase the share capital in connection with exercise of employee options | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Aug 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Betydelig vekst på tvers av virksomheten | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 11 Aug 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Significant growth across the business | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 07 Aug 2023 12:24 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 2nd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2023 14:37 CEST |
NAVAMEDIC | Report of changes in shareholdings, Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 01 Jun 2023 11:35 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 May 2023 14:16 CEST |
NAVAMEDIC | Updated recommendation by the nomination committee of Navamedic ASA | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 May 2023 08:00 CEST |
NAVAMEDIC | Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer | 20103015 Pharmaceuticals | Inside information |
| 11 May 2023 12:00 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 May 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA Q1 2023: Nok et sterkt kvartal | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 11 May 2023 08:00 CEST |
NAVAMEDIC | Navamedic ASA Q1 2023: Another strong quarter | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 10 May 2023 09:00 CEST |
NAVAMEDIC | Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag | 20103015 Pharmaceuticals | Inside information |
| 08 May 2023 10:42 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 1st quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Apr 2023 13:21 CEST |
NAVAMEDIC | Navamedic ASA: Annual Report for 2022 | 20103015 Pharmaceuticals | Annual financial and audit Reports |
| 22 Apr 2023 13:10 CEST |
NAVAMEDIC | Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB | 20103015 Pharmaceuticals | Inside information |
| 29 Mar 2023 07:31 CEST |
NAVAMEDIC | Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million | 20103015 Pharmaceuticals | Inside information |
| 03 Mar 2023 12:58 CET |
NAVAMEDIC | Flagging notification Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 16 Feb 2023 12:01 CET |
NAVAMEDIC | NAVAMEDIC ASA: GRANT OF OPTIONS TO PRIMARY INSIDERS | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 16 Feb 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Q4 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 16 Feb 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Resultater for fjerde kvartal 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 13 Feb 2023 09:00 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 4th quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Jan 2023 10:28 CET |
NAVAMEDIC | Navamedic ASA launches Modifast in Norway | 20103015 Pharmaceuticals | Ikke-informasjonspliktige pressemeldinger |
| 28 Dec 2022 16:38 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Nov 2022 10:05 CET |
NAVAMEDIC | Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 01 Nov 2022 08:00 CET |
NAVAMEDIC | Navamedic ASA: Q3 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 01 Nov 2022 08:00 CET |
NAVAMEDIC | Navamedic ASA: Resultater for tredje kvartal 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 25 Oct 2022 15:41 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 third quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Oct 2022 08:40 CEST |
NAVAMEDIC | Navamedic ASA launches ForlaxGO® - an innovative on-the-go product for the treatment of constipation | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 12 Aug 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Resultater for andre kvartal og første halvår 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 12 Aug 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Q2 and first half 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 09 Aug 2022 14:22 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 second quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 Aug 2022 14:09 CEST |
NAVAMEDIC | Navamedic ASA - Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig® | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 04 Jul 2022 19:23 CEST |
NAVAMEDIC | Navamedic ASA: Trading Update | 20103015 Pharmaceuticals | Inside information |
| 04 Jun 2022 18:39 CEST |
NAVAMEDIC | Navamedic ASA – Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 03 Jun 2022 13:21 CEST |
NAVAMEDIC | Navamedic ASA – Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 02 Jun 2022 13:49 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Jun 2022 16:07 CEST |
NAVAMEDIC | Navamedic ASA completes acquisition of Impolin AB and issues consideration shares | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 May 2022 15:53 CEST |
NAVAMEDIC | Navamedic ASA – Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 31 May 2022 14:30 CEST |
NAVAMEDIC | NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 May 2022 13:20 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 May 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Q1 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 10 May 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Resultater for første kvartal 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 09 May 2022 08:50 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 first quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 May 2022 11:35 CEST |
NAVAMEDIC | Navamedic ASA acquires Impolin AB and bolsters its product portfolio | 20103015 Pharmaceuticals | Non-regulatory press releases |